Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| A.J. Rice | UBS | 7 questions · 14% challenging |
| Justin Lake | Wolfe Research | 7 questions · 0% challenging |
| Ben Hendrix | RBC Capital Markets | 7 questions · 14% challenging |
| Ann Hynes | Mizuho Securities | 7 questions · 0% challenging |
| Steve Baxter | Wells Fargo | 6 questions · 17% challenging |
| Andrew Mok | Barclays | 6 questions · 0% challenging |
| Josh Raskin | Nephron Research | 5 questions · 0% challenging |
| Erin Wright | Morgan Stanley | 5 questions · 0% challenging |
| Whit Mayo | Leerink Partners | 5 questions · 0% challenging |
| Lance Wilkes | Bernstein | 5 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Bank of America | 2 analysts | 7 questions · 14% challenging |
| Mizuho Securities | 1 analyst | 7 questions · 0% challenging |
| RBC Capital Markets | 1 analyst | 7 questions · 14% challenging |
| UBS | 1 analyst | 7 questions · 14% challenging |
| Wolfe Research | 1 analyst | 7 questions · 0% challenging |
| Barclays | 1 analyst | 6 questions · 0% challenging |
| Wells Fargo | 1 analyst | 6 questions · 17% challenging |
| Goldman Sachs | 1 analyst | 5 questions · 0% challenging |
No 8-K events recorded for this window.
Humana delivered a Q1 performing in line to better than expectations across all early indicators, with revenue growing 23% year-over-year as the approximately 1 million new MA members contributed their first full quarter. The 2027 bid strategy prioritized margin trajectory to at least 3% by 2028, and Stars BY28 tracking was on track with BY29 showing strong early starts. Management maintained the at-least-$9 adjusted EPS guidance for 2026 with IBNR reserving up 35% versus 22% membership growth, reflecting prudent conservatism.
Margin | Competitive Dynamics | Cost Pressure | Subscriber Growth | Regulation Policy | Guidance Reliability | Capex Investment | Revenue Growth | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 6 | 5 | 4 | 1 | 6 | 4 | 2 | |
| 2025Q1 | 7 | 2 | 4 | 3 | 4 | 4 | 1 | 3 |
| 2025Q2 | 2 | 5 | 4 | 4 | 5 | 2 | 1 | 3 |
| 2025Q3 | 10 | 7 | 1 | 7 | 3 | |||
| 2025Q4 | 9 | 6 | 4 | 5 | 2 | 2 | 2 | |
| 2026Q1 | 6 | 3 | 8 | 2 | 1 | 1 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Margin | 6 | 7 | 2 | 10 | 9 | 6 |
| Competitive Dynamics | 5 | 2 | 5 | 7 | 6 | 3 |
| Cost Pressure | 4 | 4 | 4 | 1 | 4 | 8 |
| Subscriber Growth | 1 | 3 | 4 | 7 | 5 | 2 |
| Regulation Policy | 6 | 4 | 5 | 3 | 2 | 1 |
| Guidance Reliability | 4 | 4 | 2 | 2 | 1 | |
| Capex Investment | 2 | 1 | 1 | 2 | 1 | |
| Revenue Growth | 3 | 3 | 1 |
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $29.21B | +10.4% | $-5.76 | -30.3% | -1.9% | -2.4% | $-682M |
| FY2025 Q1 | $32.11B | +8.4% | $10.30 | +68.6% | 6.3% | 3.9% | $236M |
| FY2025 Q2 | $32.39B | +9.6% | $4.51 | -19.8% | 3.4% | 1.7% | $1.16B |
| FY2025 Q3 | $32.65B | +11.1% | $1.62 | -59.3% | 1.2% | 0.6% | $836M |
| FY2025 Q4 | $32.52B | +11.3% | $-6.61 | -14.8% | -2.5% | -2.4% | $-1.85B |
| FY2026 Q1Selected | $39.65B | +23.5% | $9.83 | -4.6% | 4.4% | 3.0% | $1.13B |
| FY2026 Q2 | $40.87B | +26.2% | $5.73 | +27.1% | 3.3% | 1.7% | $1.83B |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q1 2026Earnings call Apr 29, 2026
FY2026 Q1 in brief
Humana delivered a Q1 performing in line to better than expectations across all early indicators, with revenue growing 23% year-over-year as the approximately 1 million new MA members contributed their first full quarter.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
GAAP revenue YoY +23.5% → base 8. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for Humana (HUM), FY2026 Q1: 7/10. Scores: Humana’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: HUM daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
What HUM said about other companies on its FY2026 Q1 call, and what other companies said about HUM on their calls covering the same calendar quarter (Q1 2026). Each company's own fiscal quarter is shown next to its name. Extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“some timing-related items related to the Villages Health acquisition that as we continue to integrate, we'll see improvement for the rest of the year.”
Humana is integrating its Villages Health acquisition within CenterWell.
“I would say that Welsh Carson has been an amazing partner to us, and we're proud of what we've built together”
Welsh Carson is Humana's private-equity JV partner in its CenterWell primary-care clinics, with put/call decisions pending.
“we recently completed the acquisition of Max Health. This is a Florida-based primary care organization that will expand CenterWell's reach into new critical markets.”
Humana closed the acquisition of Max Health, a Florida primary-care organization, to expand CenterWell.
| Company | Score | Trend | Rev YoY | Headline |
|---|---|---|---|---|
| HUMHumana | 7 | +23.5% | Q1 performing in line to better than expectations across all early indicators | |
| CICigna | 8 | +4.6% | Specialty & Care Services Delivers 20% Earnings Growth | |
| CNCCentene Corporation | 9 | +7.1% | Full Year EPS Guidance Raised to Greater Than $3.40 | |
| CVSCVS Health | 9 | +6.2% | Strong earnings growth and comprehensive guidance raise | |
| ELVElevance Health | 7 | +2.6% | Full year EPS guidance raised on strong Q1 execution | |
| UNHUnitedHealth Group Incorporated | 7 | +2.0% | MCR Improved 90bps To 83.9% On Pricing And Cost Management |
Q1 performing in line to better than expectations across all early indicators
| Company | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|---|
| HUM | 5 | 6 | 6 | 5 | 6 | 7 |
| CI | 7 | 7 | 6 | 6 | 7 | 8 |
| CNC | 7 | 9 | 3 | 7 | 6 | 9 |
| CVS | 6 | 9 | 8 | 9 | 7 | 9 |
| ELV | 6 | 6 | 4 | 6 | 4 | 7 |
| UNH | 6 | 3 | 2 | 4 | 5 | 7 |
Full year EPS guidance raised on strong Q1 execution
MCR Improved 90bps To 83.9% On Pricing And Cost Management